Abbott Laboratories reported Q3 2026 results with adjusted earnings per share of $1.42, matching estimates, and revenue of $13.01 billion, slightly above expectations. Despite 14.5% sales growth, the company lowered its 2026 sales growth forecast due to weakness in the medical device market but reaffirmed full-year earnings guidance. A major strategic move is Abbott's plan to spin off its nutrition business, which generates about $8.5 billion annually, into an independent company. This separation will reshape Abbott's business portfolio, though the timing of the spin-off has not been disclosed.
Abbott Laboratories trades at USD 99.68 on Pluang as of Oct 21, 2026 21:31 WIB, down 2.94% for the day. The stock's market cap is $177.28 billion with a dividend yield of 2.46%. Investor interest remains strong with 67% of orders to buy and a typical hold time of 96 days.
Abbott posted a 14.5% increase in reported sales and 7.0% comparable sales growth for Q3 2026, with GAAP diluted EPS of $0.53 and adjusted EPS of $1.42. The company expanded its portfolio with FDA approvals for innovative products like the Libre Duo ...
Abbott announced plans to separate its Nutrition business into a standalone, publicly traded company by the end of 2027. The new Nutrition company will focus on the growing healthy nutrition market with $8.5 billion in annual sales and iconic brands ...
